RCA 101
Alternative Names: RCA-101; RNA Cognitive Advantage - CognigenicsLatest Information Update: 07 Jul 2023
At a glance
- Originator Cognigenics
- Class Anxiolytics; Gene therapies; RNA
- Mechanism of Action 5-HT2A serotonin receptor expression inhibitors; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anxiety disorders
Most Recent Events
- 27 Jun 2023 Cognigenics intends to file an IND application with the US FDA in US for Anxiety in 2024 (Cognigenics website, June 2023)
- 27 Jun 2023 Cognigenics intends to launch RCA 101 till 2025 (Cognigenics website, June 2023)
- 27 Jun 2023 Cognigenics plans clinical trials for mental disorders in 2024 (Intranasal)